35f68daa-0cea-40de-99b8-446d9e9784c8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.400
- PROTEIN_SECRETION+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
- ANDROGEN_RESPONSE+0.300
- TGF_BETA_SIGNALING+0.300
- G2M_CHECKPOINT+0.200
- HEME_METABOLISM+0.200
- INTERFERON_ALPHA_RESPONSE+0.200
- INTERFERON_GAMMA_RESPONSE+0.200
- MTORC1_SIGNALING+0.200
Top 10 suppressed
- KRAS_SIGNALING_DN-0.400
- PANCREAS_BETA_CELLS-0.400
- COAGULATION-0.300
- HEDGEHOG_SIGNALING-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- APICAL_JUNCTION-0.200
- MYOGENESIS-0.200
- ALLOGRAFT_REJECTION-0.100
- ANGIOGENESIS-0.100
- APICAL_SURFACE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031137_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.732 |
| 2 | DRR168568 | — | — | 0.715 |
| 3 | SRR934795 | — | — | 0.712 |
| 4 | MDT-AP-3313 | Med | Medulloblastoma | 0.709 |
| 5 | MNG1027 | — | — | 0.705 |
| 6 | TCGA-44-2662-01A-01R-A278-07 | — | cohortMD2 | 0.704 |
| 7 | SJEPD031138_D1.RNA-Seq | EPN | Supratentorial EPN | 0.698 |
| 8 | TCGA-78-7146-01A-11R-2039-07 | — | cohortA1 | 0.694 |
| 9 | MBCproject_0107_T1_RNA | — | B | 0.691 |
| 10 | TCGA-AR-A24Z-01A-11R-A169-07 | — | B | 0.686 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.200 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |